Sign up to save tools and stay up to date with the latest in AI
bg
bg
1

Information blocking fines are now fair game in health care

Sep 05, 2023 - statnews.com
Health IT vendors and health information networks could face up to $1 million in penalties for obstructing the transfer of patients' electronic health information, a practice known as information blocking. The Health and Human Service Department’s Office of the Inspector General will oversee these penalties. Meanwhile, tech giants like Microsoft, Google, and Amazon are exploring the potential of generative AI in healthcare, despite the lack of clear ethical and regulatory guidelines. To monitor the progress of generative AI, STAT has launched a tracker that catalogs new applications.

In other news, Babylon Health, a British telehealth and AI company, has sold most of its assets to eMed after filing for bankruptcy and laying off about 100 employees. Walgreens is also in the news as it begins its search for a new CEO following the stepping down of Rosalind Brewer. The company has recently acquired health companies like VillageMD and CareCentrix as it prioritizes its consumer health business and localized healthcare.

Key takeaways:

  • Health IT vendors and health information networks could face penalties up to $1 million for obstructing the transfer of patients' electronic health information, a practice known as information blocking.
  • Generative AI is expected to fundamentally change health care over the next few years, with tech giants like Microsoft, Google, and Amazon already introducing the technology for health care customers.
  • Babylon Health, a British telehealth and AI company, has sold most of its assets to eMed after filing for bankruptcy, shutting down U.S. operations, and laying off about 100 employees.
  • Walgreens' CEO Rosalind Brewer is stepping down, and the company has begun its search for a new CEO. The company has recently acquired health companies like VillageMD and CareCentrix and has moved deeper into connecting customers with clinical trials.
View Full Article

Comments (0)

Be the first to comment!